ChromaDex releases results of clinical trial demonstrating anti-inflammatory effects of NR
Longevity Technology - 28-Jan-2022Gold-standard trial included 35 participants taking 1000mg of NR (or placebo) for a week
Join the club for FREE to access the whole archive and other member benefits.
Senior Investigator at NHLBI Laboratory of Mitochondrial Biology and Metabolism
Michael Sack graduated with his M.B.B.Ch. and M.Sc. from the University of Witwatersrand and earned his Ph.D. in 2000 from the University of Cape Town in South Africa. He did his internship at Johannesburg General Hospital and his internal medicine residency at Georgetown University Medical Center. He conducted cardiology research and did a clinical fellowship at Washington University Medical Center from 1994 to 1997.
Dr. Sack joined the NHLBI in 2003. Dr. Sack has authored or coauthored more than 100 papers, editorials, reviews, and book chapters. He currently sits on the editorial boards of the Journal of Molecular and Cellular Cardiology, Mitochondrion, Journal of Gerontology, and Drug Discovery Today and is a member of the American Society for Clinical Investigation.
Visit website: https://irp.nih.gov/pi/michael-sack
See also: National Institutes of Health (NIH) - Medical research agency that supports scientific studies
Details last updated 28-Jan-2022
Gold-standard trial included 35 participants taking 1000mg of NR (or placebo) for a week